Status: Recruiting
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Participants needed: 190
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: MaleType: InterventionalSponsor: Arsenal Biosciences, Inc.Updated: Jun 5, 2026Locations: 9
Eligibility criteria
At least 18 years of age at time of signing informed consent form. [+3]
Any prior systemic therapy for CRPC within 14 days prior to scheduled protocol r... [+2]